Hemostats Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Hemostats 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group,  t i t l ed  "Hemostats  Market :  
Global  Industry  Trends,  Share ,  S ize ,  Growth,  Opportuni ty  and Forecast  
2024-2032,"  the  g loba l  hemosta ts  marke t  s ize  reached US$ 3 .5  B i l l ion  in  
2023.
Report Hemostats  a re  u t i l i zed  in  d i f fe rent  su rg ica l  p rocedures to  s top  b leed ing .  
These  agents  a re  employed  in  the  ear ly  phases fo r  in i t ia l  inc is ions and 
Highlight and c los ing  b lood  vesse ls  un t i l  l iga t ion .  
They he lp  decrease  wound hea l ing and  opera t i ve  t ime,  o f fer ing  be t te r  
management  o f  an t icoagu la ted pa t ien ts  and reduc ing  the pa t ien t  recovery  
Description per iod .  A t  p resent ,  numerous  surg ica l  hemosta t i c  agen ts  a re  ava i lab le  in  the 
marke t  w i th  vary ing costs ,  compos i t ion ,  app l i ca t ion,  adherence ,  
immunogen ic i ty  and mechan ism o f  ac t ion .
Request  for  a  PDF sample  of  th is  report :  
ht tps : / /www. imarcgroup.com/hemosta ts -marke t / requestsample
Report Description
Global  Hemosta ts  Market  Trends :
There  is  a  s ign i f i can t  r i se  in  the  demand fo r  hemosta ts  on  accoun t  o f  t he  g row ing  p reva lence  o f  f a ta l  i n ju r ies ,  
ch ron ic  d iso rde rs ,  cesa rean  de l ive r ies  and  ma jo r  o rgan  su rge r ies .  Hemosta ts  he lp  p reven t  b lood  loss  dur ing  
su rg ica l  p rocedures ,  espec ia l l y  f o r  nonana tomic  and  sens i t i ve  s t ruc tu res ,  and  among pa t ien ts  w i th  hemosta t i c  
abnorma l i t i es .  Apar t  f rom th is ,  t he  r i s ing  ger ia t r i c  popu la t ion ,  a long  w i th  the  inc reas ing  number  o f  m in ima l l y  
invas ive  (MI )  su rger ies ,  a re  s t reng then ing  the  g rowth  o f  t he  marke t .  
Fur the rmore ,  techno log ica l  advancemen ts  and  improv ing  hea l thcare  spend ing  i s  d r i v ing  the  marke t  g rowth .  
However ,  on  accoun t  o f  the  sudden  ou tb reak  o f  the  co ronav i rus  d isease  (COVID-19) ,  hea l thcare  p rov ide rs  a re  
cu r ren t l y  l im i t i ng  the  number  o f  su rg ica l  p rocedu res  to  p reven t  t he  sp read  o f  t he  pandemic ,  wh ich  i s  nega t ive ly  
impac t ing  the  marke t  g rowth .
Look ing  forward ,  the  market  va lue  is  pro jected to  reach US$ 5 .8  B i l l ion  by  2032 ,  expanding a t  a  CAGR of  
5 .73% dur ing  the  forecas t  per iod (2024-2032) .
V iew Repor t  TOC,  F igures  and  Tables :  h t tps: / /www. imarcgroup.com/hemostats -marke t
Breakup by Product:
• Thrombin Based
• Combinat ion Based
• Oxidized Regenerated Cel lulose Based
• Gelat in Based
• Collagen Based
Report 
Breakup by Application:
Segmentation • Orthopedic Surgery
• General  Surgery
• Neurological  Surgery
• Cardiovascular Surgery
• Reconstruct ive Surgery
• Gynecological  Surgery
• Others
Breakup by Formulation:
• Matrix and Gel Hemostats
• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats
Report Breakup by Region:
Segmentation • North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Arch Therapeutics Inc.
• Baxter International  Inc.
• B. Braun Melsungen Aktiengesel l
Competitive • C. R. Bard Inc.
Landscape • GELITA MEDICAL GmbH
• Integra Li feSciences Corporation
with Key • Johnson & Johnson
Players • Pfi zer Inc.
• Stryker Corporation
• Telefl ex Incorporated
• Z-Medica LLC
How has the global hemostats market performed so 
far and how will it perform in the coming years?
What has been the impact of COVID-19 on the 
global hemostats market?
Key 
Questions What are the key regional markets?
Answered in 
What is the breakup of the market based on the 
the Report product?
What is the breakup of the market based on the 
application?
What is the breakup of the market based on the 
formulation?
What are the various stages in the value chain of 
the industry?
What are the key driving factors and challenges in 
the industry?
Key 
Questions What is the structure of the global hemostats market and who are the key players?
Answered in 
the Report What is the degree of competition in the industry?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  H e m o s t a t s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  P r o d u c t
    6 . 1     T h r o m b i n  B a s e d
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     C o m b i n a t i o n  B a s e d
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     O x i d i z e d  R e g e n e r a t e d  C e l l u l o s e  B a s e d
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     G e l a t i n  B a s e d
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     C o l l a g e n  B a s e d
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  A p p l i c a t i o n
    7 . 1     O r t h o p e d i c  S u r g e r y
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     G e n e r a l  S u r g e r y
Table of         7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     N e u r o l o g i c a l  S u r g e r y
Contents         7 . 3 . 1  M a r k e t  T r e n d s        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     C a r d i o v a s c u l a r  S u r g e r y
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     R e c o n s t r u c t i v e  S u r g e r y
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
    7 . 6     G y n e c o l o g i c a l  S u r g e r y
        7 . 6 . 1  M a r k e t  T r e n d s
        7 . 6 . 2  M a r k e t  F o r e c a s t
    7 . 7     O t h e r s
        7 . 7 . 1  M a r k e t  T r e n d s
        7 . 7 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /h em o sta t s -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: